Publicacións en colaboración con investigadores/as de Clínica Universitaria de Navarra (16)

2024

  1. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

    Haematologica

  2. CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy?

    Hemato, Vol. 5, Núm. 2, pp. 171-179

  3. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  4. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  5. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

    HemaSphere

  6. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

  7. Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast

    Advances in Therapy

  8. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Haematologica, Vol. 109, Núm. 7, pp. 2219-2228

2022

  1. Post-CAR-T cell therapy (consolidation and relapse): Multiple myeloma

    The EBMT/EHA CAR-T Cell Handbook (Springer International Publishing), pp. 173-176

2020

  1. Article18 f-fdg and11 c-methionine pet/ct in newly diagnosed multiple myeloma patients: Comparison of volume-based pet biomarkers

    Cancers, Vol. 12, Núm. 4

  2. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    The Lancet Oncology, Vol. 21, Núm. 2, pp. 207-221

2019

  1. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

    Blood Cancer Journal, Vol. 9, Núm. 4

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2010

  1. Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia

    Cancer Science, Vol. 101, Núm. 2, pp. 425-432

2009

  1. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

  2. Expansion of CD8+CD57+ T cells in an immunocompetent patient with acute toxoplasmosis

    Advances in Hematology, Vol. 2009